ライフサイエンスコーパス: LT

1 LT indication was defined as DC if the Model for End-Sta

2 LT is complex surgery and the increasing use of high-ris

3 LT recipients needing full assistance (KPS 10%-40%) vs b

4 LT with very old donors has historically been associated

5 LT-Fam also attained higher power than other methods in

6 LT-scanner's performance is evaluated based on its abili

7 LT/HV patients had higher stage disease (P < 0.001), but

8 LTs catalyze the non-hydrolytic cleavage of the bacteria

9 lticenter study included 911 patients from 3 LT centers with short, medium, and long wait times (medi

10 Six episodes of acute rejection (n = 2 KT, 4 LT) occurred, during hepatitis C virus treatment in 4 an

11 In 47 LT recipients, 10 developed grade 3 PGD, which was obvio

12 g-term renal and survival outcomes among 576 LT recipients who received SRL in a medical center betwe

13 In a cohort of 598 LT recipients from July 1, 2009 to November 30, 2014, mu

14 d were 443 posttransplant patients (KT = 60, LT = 347, DLK = 36); 42% had cirrhosis, and 54% had fail

15 Of the 665 LT recipients, 457 (68.7%) had AFP-producing tumors, and

16 2 control groups without prior angiogram, 72 LT recipients matched for cardiovascular risk factors (c

17 Compared with 747 LT recipients not receiving LRT, 2854 receiving LRT had

18 values, central corneal thickness, WtW, ACD, LT, and axial length both before and after cycloplegia.

19 Of 34,975 adult LT recipients, 16,472 (47.1%) were transplanted after th

20 a retrospective cohort study of 34 402 adult LTs between 2002 and 2013 using Vizient inpatient claims

21 ansplant Analysis and Research-file of adult LTs from 2002 to 2014.

22 After LT, DRESS recurrence was observed in 3 of 5 patients.

23 14 fragment]) were obtained before and after LT (0 [H0], 6, 12, 24, 48 and 72 hours after pulmonary a

24 nts on the transplant waiting list and after LT.

25 disease recurrence and clinical course after LT.

26 increased risk of perioperative death after LT.

27 Overall survival estimates after LT were 80%, 77%, and 77% at 6 months, 1 year, and 3 yea

28 iated to collect the experience on EVR after LT with the aim of providing guidance for transplant cli

29 ischarged to a rehabilitation facility after LT (22% vs 3%) and be rehospitalized within the first po

30 tors for CRE acquisition and infection after LT.

31 nd mortality from de novo malignancies after LT.

32 nd within 6 months and beyond 6 months after LT.

33 s 4 h following U0126 exposure but not after LT exposure.

34 related mortality in patients with PSC after LT.

35 r Organ Sharing database was queried for all LT performed in the United States between 1994 and 2014.

36 Retrospective single-center study of all LT since the start of DCD program (2001-2015).

37 o compare characteristics and outcomes among LT recipients with radiographically apparent HCC lesions

38 ciency and proteinuria remains unclear among LT recipients receiving sirolimus.

39 cing tumors (the maximum AFP level before an LT was </=10 ng/mL).

40 nter of 665 adults with HCC who underwent an LT during the period from 1989 to 2013.

41 es are equivalently attenuated in IL-33- and LT-deficient mice, and optimal ILC2 activation reflects

42 In both groups, ACD and LT changed significantly (P < .001).

43 ST- and LT-IH treated rats exhibited hypertension, irregular bre

44 arterial hypertension-targeted therapies and LT in patients who are transplantation candidates.

45 teroid-resistant cascade of Wnt5a, Tgm2, and LTs, which might represent a therapeutic target for airw

46 a suggest that females may benefit from anti-LT therapy to a greater extent than males, prompting con

47 herapy after a temporary interruption around LT was highly effective, achieving sustained virological

48 ients who had treatment interruptions around LT were identified.

49 Before antiretroviral therapy (ART), LTs contained >98% of the SIV RNA(+) and DNA(+) cells.

50 mpled to induce family-biased ascertainment, LT-Fam was correctly calibrated whereas ATT, MLM, and CA

51 th family-biased case-control ascertainment, LT-Fam was correctly calibrated (average chi(2) = 1.00-1

52 ncluded model for end-stage liver disease at LT >23, time to recurrence, >3 recurrent nodules, maximu

53 patients with mPAP of 35 mm Hg or greater at LT and correlate their clinical outcomes with hemodynami

54 d elevated international normalized ratio at LT were associated with increased nonskin cancer risk.

55 that enrolled adults with cirrhosis awaiting LT and treated with bridging or down-staging therapies b

56 For adults with T2 HCC awaiting LT, transplant with any bridging therapy showed a nonsig

57 proach to the treatment of patients awaiting LT which may be assessed in future studies.

58 should receive HCV treatment while awaiting LT is between 23 and 27, depending on the UNOS region.

59 of PoPH diagnosis, at last evaluation before LT, and within 6 months and beyond 6 months after LT.

60 , at the national level, treating HCV before LT increased life expectancy if MELD was </=27 but could

61 therapy using LDV/SOF with ribavirin before LT is the most cost-effective strategy for patients with

62 erial hypertension-targeted therapies before LT resulted in significant decreases in both mPAP (36 +/

63 th bridging or down-staging therapies before LT.

64 of LDV/SOF therapy at which treatment before LT is cost-effective is US $177 381.

65 nd the water molecules inside the pore, both LT and RT data sets are consistent with the positions ob

66 .11] at baseline vs 6.25 [4.27] after bright LT, and 8.87 [2.83] at baseline vs 7.33 [3.52] after dim

67 ] at baseline vs 106.98 [19.37] after bright LT, and 95.11 [19.86] at baseline vs 99.28 [16.94] after

68 Both bright LT and dim-red LT were associated with improvements in s

69 ipants were randomized 1:1 to receive bright LT or dim-red LT (controlled condition) twice daily in 1

70 ] disease duration, 5.9 [3.6] years), bright LT resulted in significant improvements in EDS, as asses

71 nt cardiorespiratory abnormalities caused by LT-IH are mediated by epigenetic re-programming of the r

72 ctors (control group I), and 119 consecutive LT recipients without any CV risk factors (control group

73 In contrast, LT as low as 536 V/cm were found for 2 mus asymmetric H-

74 Hdac8-deficient LT-HSCs displayed hyperactivation of p53 and increased a

75 Despite more advanced disease, LT/HV patients had superior unadjusted survival (20.3 vs

76 unctional status (KPS 10%-40%), living donor LT, pre-LT hemodialysis, and the donor risk index (all P

77 All adult deceased donor LTs from January 1, 2010, to March 31, 2016, were includ

78 Treating rats with decitabine either during LT-IH or during recovery from LT-IH prevented DNA methyl

79 , a DNA methylation inhibitor, either during LT-IH or during recovery from LT-IH, prevented DNA methy

80 thogen Pseudomonas aeruginosa encodes eleven LTs.

81 id (E873p3) together with the genes encoding LT and STp.

82 ockdown of each of these E3 ligases enhances LT stability and promotes MCV genome replication.

83 functions to modulate p53 activity to ensure LT-HSC maintenance and cell survival under stress.

84 ipients hospitalized >/=30 days in the first LT year were typically smaller volume and/or transplanti

85 Bronchoalveolar lavage fluid LT levels were increased in neonatal and adult but reduc

86 Following LT, CF-adapted Pseudomonas strains, potentially originat

87 gle-center report of recurrent HCC following LT, surgical treatment in well-selected patients is asso

88 We studied outcomes of candidates for LT suffering from PoPH.

89 tly, NASH has increased as an indication for LT in this age group.

90 A total of 47,591 adults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic s

91 conducted an analysis of patients listed for LT in the United Network for Organ Sharing/Organ Procure

92 arge benefit ratio should be prioritized for LT.

93 4458 were delisted for being "too sick" for LT.

94 nce and should be the preferred strategy for LT recipients with undetectable or low-level viremia at

95 For adults with T1 HCC and waiting for LT, there were only two nonrandomized comparative studie

96 HCV patients with HCC or DCC waitlisted for LT.

97 HCC patients and DCC patients waitlisted for LT.

98 alized during recovery from ST- but not from LT-IH.

99 either during LT-IH or during recovery from LT-IH prevented DNA methylation of AOE genes, normalized

100 either during LT-IH or during recovery from LT-IH, prevented DNA methylation, normalized the express

101 ch can be utilized for prioritization of HCC LT candidates.

102 osttransplant follow-up should take the HEHE-LT score into account.

103 However, LT is not curative and only bone marrow transplantation

104 under a liability threshold model; however, LT-Fam uses published narrow-sense heritability estimate

105 Our objective was to identify LT-eligible patients with decompensated cirrhosis who wo

106 with structural information further improves LT-scanner performance.

107 ntions aimed at managing these conditions in LT candidates.

108 Our findings reveal age differences in LT and Wnt pathways during airway inflammation and ident

109 ive guidelines on use of everolimus (EVR) in LT are still lacking.

110 es, prompting consideration of sex issues in LT modifier development.

111 h evidence of continuing virus production in LT despite ART, indicated two important sources for rebo

112 o identify factors influencing recurrence in LT recipients with non-AFP-producing tumors.

113 plus daclatasvir was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not

114 We aim to assess survival in LT recipients based on presence, severity, extent of CAD

115 ode the heat-stable (ST) and/or heat-labile (LT) enterotoxins, as well as surface structures, known a

116 lar angiogenesis and diminishing lactotroph (LT) VEGFR2 expression, lifting reproductive axis repress

117 Human leukotriene (LT) A4 hydrolase/aminopeptidase (LTA4H) is a bifunctiona

118 -stimulated neutrophils produce leukotriene (LT)B4, we examined the effect of propofol on LTB4 produc

119 Proinflammatory leukotrienes (LTs) are produced by 5-lipoxygenase (5-LO) aided by 5-LO

120 accumulation of protoporphyrin in the liver, LT without hematopoietic stem cell transplantation leave

121 Similar to LTMLM, LT-Fam is computed from posterior mean liabilities (PML)

122 We show that evolutionarily conserved MCV LT phosphorylation sites are constitutively recognized b

123 We report a template-based method, LT-scanner, which scans the human proteome using protein

124 Moreover, LT/HV patients had shorter hospitalizations (9 vs 12 day

125 n = 152) and 19.4% (n = 13) of "CF negative" LT + STp (n = 67) expressing isolates analyzed harbored

126 lude that CS30 is common among "CF negative" LT + STp isolates and is associated with ETEC that cause

127 hat we use is demonstrated by the ability of LT-scanner to identify the known targets of FDA-approved

128 ; n = 405 of 2,103; 19.2%) had no benefit of LT compared to alternative treatments.

129 stoperative cardiac events within 90 days of LT predicted poor survival in study group as well as con

130 of CAD, and cardiac events within 90 days of LT.

131 To determine the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with

132 However, the downstream mediators of LT toxicity remain elusive.

133 recipient matching criteria, the outcomes of LT with donors >/=70 and <70 years are comparable with a

134 required to determine optimal parameters of LT for PD.

135 The rate of LT WL for HCV complicated by DC has decreased by over 30

136 Simulation of LT integrated data from recent trials of oral direct-act

137 At the time of LT, 39% of recipients had PH (mPAP >/= 25 mm Hg) and 10.

138 ence: microvascular invasion, AFP at time of LT, and the sum of the largest viable tumor diameter and

139 eous kidney transplantation (KT) (at time of LT, group 1) and 61 with delayed KT (performed at a late

140 undetectable or low-level viremia at time of LT.

141 on a very large patient cohort, the value of LT in the management of HEHE and to identify risk factor

142 cipient cohort clearly confirms the value of LT in the treatment of this rare disorder and also permi

143 in gonadotroph function opposite to those of LTs, with up-regulation and down-regulation of gonadotro

144 Outcomes of all types of LTs were compared according to 4 study groups: patients

145 Aged rats treated ST or LT with FKBP1b substantially outperformed age-matched ve

146 Rats exposed to either ST- or LT-IH exhibited hypertension, irregular breathing with a

147 liver transplantation (LT) compared to other LT recipients.

148 risk factors for CMV infection in pediatric LT recipients managed with ganciclovir-based preemptive

149 However, the frequency of phenotypic LT-HSC population was significantly higher shortly after

150 hepatitis B core antigen (anti-HBc)-positive LT recipient.

151 Post-LT CRE infection was identified in 59 (15.7%) Klebsiella

152 Post-LT de novo nonskin cancer decreased overall posttranspla

153 Post-LT survival was 98% and 94% at 1 and 5 years, respective

154 eptor autoantibodies pre-LT, and year 1 post-LT.

155 Recurrence-free survival and post-LT recurrence were compared among 3601 MC patients with

156 Transplantation-free and post-LT survival was 56% and 60%, respectively.

157 r CRE infection were acquisition of CRE post-LT, Model for End-Stage Liver Disease score greater than

158 d the host microbiota within three days post-LT, in association with a reduction in richness and dive

159 T dialysis was the only risk factor for post-LT CRE acquisition.

160 nate surveillance imaging schedules for post-LT hepatocellular carcinoma patients.

161 tment regimens that are recommended for post-LT patients are not safe in patients with severe renal i

162 o not address the treatment options for post-LT patients with severe renal impairment or who are on d

163 f HEHE and to identify risk factors for post-LT recurrence.

164 verity or extent of CAD does not impact post-LT survival, if appropriately revascularized.

165 had superior 5-year RFS (72%) and lower post-LT recurrence (HR 0.52, P < 0.001) compared with both un

166 3 treatment-naive HCV genotype 1a male post-LT patients on hemodialysis who were treated with EBR/GZ

167 Median post-LT follow-up was 7.6 years (interquartile range, 2.8-14.

168 One patient had HBV viremia 16 months post-LT without detectable HBsAg.

169 st sensitive to the utility of patients post-LT, treatment sustained virological response rates, LT c

170 n response to LRT independently predict post-LT recurrence, serving as a surrogate for underlying tum

171 s time to diagnosis of first recurrence post-LT by surveillance imaging.

172 nd an increased risk for HCC recurrence post-LT.

173 patient-level, whereas center-specific post-LT healthcare utilization is associated with certain cen

174 of RETREAT, which may help standardize post-LT surveillance, provide a framework for tumor staging a

175 Multivariate analysis showed that post-LT dialysis was the only risk factor for post-LT CRE acq

176 8.7 and $283,789, respectively, in the post-LT arm.

177 nd patients on dialysis, but not in the post-LT setting.

178 include variables from the first three post-LT days only (AUROC of 0.818, 0.776-0.856, p = 0.001).

179 ing long-term outcomes of pre-LT versus post-LT HCV treatment with oral direct-acting antivirals for

180 nd cost outcomes based on pre-LT versus post-LT treatment with an all-oral DAA regimen.

181 Characteristics associated with post-LT HCC recurrence.

182 regression, HCC was not associated with post-LT survival among all patients (hazard ratio, 1.15; 95%

183 pre-LT hospitalization predicts 1-year post-LT hospitalization independent of MELD score at the pati

184 Similar 5-year post-LT OS rates (73.2% and 73.0% for Group LDLT and Group BD

185 vs 85%, 75%, 68%; P = 0.490) and 5-year post-LT recurrence (11.2% vs 10.1%; P = 0.474).

186 RETREAT was able to stratify 5-year post-LT recurrence risk ranging from less than 3% with a scor

187 pendently associated with higher 1-year post-LT transplant costs were older age, poor functional stat

188 e and out of the hospital (DAOH) 1 year post-LT.

189 ion (hazard ratio [HR], 4.8; P < 0.001), pre-LT waiting time of 120 days or less (HR, 2.6; P = 0.01)

190 othelin-1 type A receptor autoantibodies pre-LT, and year 1 post-LT.

191 In conclusion, pre-LT hospitalization predicts 1-year post-LT hospitalizati

192 ociation between hospitalization 90 days pre-LT and the number of days alive and out of the hospital

193 Hospitalization in the 90 days pre-LT was inversely associated with DAOH (beta = -3.4 DAOH/

194 e analysis, recipient's age and elevated pre-LT international normalized ratio were associated with i

195 who would benefit (and not benefit) from pre-LT treatment based on their Model for End-Stage Liver Di

196 n, the threshold MELD score to treat HCV pre-LT varied between 23 and 27 and was lower for UNOS regio

197 DAOH (beta = -3.4 DAOH/week hospitalized pre-LT; P = .002).

198 l status (KPS 10%-40%), living donor LT, pre-LT hemodialysis, and the donor risk index (all P < .001)

199 ipients with HBV DNA less than 100 IU/mL pre-LT.

200 e invasion (HR = 2.2; P = 0.03), but not pre-LT extrahepatic disease, were significant risk factors f

201 ghty-seven LT recipients with history of pre-LT angiogram (December 2005 to December 2012) were compa

202 al trial comparing long-term outcomes of pre-LT versus post-LT HCV treatment with oral direct-acting

203 their health and cost outcomes based on pre-LT versus post-LT treatment with an all-oral DAA regimen

204 When only pre-LT factors were considered, wait time of less than 6 or

205 licy research; our results indicate that pre-LT treatment with a highly effective, all-oral DAA regim

206 In the DCC analysis, the pre-LT treatment strategy resulted in 9.27 per-patient quali

207 As such, the pre-LT treatment strategy was found to be the most cost-effe

208 LD] score >/=35, inpatient or ventilated pre-LT).

209 We analyzed 1269 primary LT recipients from 1 of 2000 to 4 of 2009 with known HLA

210 However, 5-year OS for CLRT and primary LT was not significantly different among patients with (

211 ell-compensated cirrhosis instead of primary LT because it may lead to better utilization of donor li

212 nts with CLRT and 4119 patients with primary LT).

213 atment sustained virological response rates, LT costs, and baseline Model for End-Stage Liver Disease

214 ive in controlling CMV in children receiving LT, with lower costs and lower exposure to antivirals.

215 Patients receiving LT for IBDI were more likely women (54.1%, P = 0.001), h

216 ndomized 1:1 to receive bright LT or dim-red LT (controlled condition) twice daily in 1-hour interval

217 Both bright LT and dim-red LT were associated with improvements in sleep quality as

218 83] at baseline vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.4

219 ] at baseline vs 99.28 [16.94] after dim-red LT).

220 Del-1 deficiency in mice resulted in reduced LT-HSC proliferation and infringed preferentially upon m

221 to 2014 to obtain the number of NASH-related LT waitlist additions.

222 forecast obesity estimates and NASH-related LT waitlist additions.

223 ias in the efficiency of clinically relevant LT biosynthesis inhibitors, showing that their effects a

224 of pediatric patients undergoing sequential LT and stem cell transplantation have been described in

225 Eighty-seven LT recipients with history of pre-LT angiogram (December

226 inhibitor reduces Skp2 levels and stabilizes LT, leading to enhanced MCV replication and transmission

227 ses, which degrade and suppress steady-state LT protein levels.

228 roduce a family-based association statistic (LT-Fam) that is robust to this problem.

229 ed infection and requires an active large T (LT) phosphoprotein helicase to replicate.

230 ribed by the RT than by the low-temperature (LT) crystal structure.

231 ither short-term (ST; 10 days) or long-term (LT, 30 days) IH.

232 rats at either 13 months of age (long-term, LT) or 19 months of age (short-term, ST) and tested memo

233 ectroporation thresholds were 54% lower than LTs for symmetric waveforms and 33% lower for asymmetric

234 Taken together, these findings indicate that LT reduces c-Jun protein levels via two distinct mechani

235 Here we report that LT exposure rapidly reduces the levels of c-Jun, a key r

236 stored c-Jun protein levels, suggesting that LT promotes degradation of c-Jun protein.

237 The LT, VL, AL, and LAF were not significantly different amo

238 Human ILC2s expressed the LT receptor CysLT1, levels of which were increased in at

239 cause these sex differences by impeding the LT-biosynthetic 5-LO/FLAP complex assembly.

240 We sought to study the activation of the LT and Wnt pathways during early- or late-onset allergic

241 ke projections for future NASH burden on the LT waitlist.

242 agement of patients with HCC who were on the LT waitlist.

243 in cirrhosis that can be detrimental to the LT candidate.

244 in obesity and NASH-related additions to the LT waitlist in the United States and make projections fo

245 are foundational to an understanding of the LTs as catalysts and as antibiotic targets.

246 Light therapy (LT), a widely available treatment modality in sleep medi

247 irty-one distinct products distinguish these LTs with respect to substrate recognition, catalytic act

248 e, the lens densitometry and lens thickness (LT) measurements were performed after dilation of the pu

249 2.5 mm and 3.0 mm diameter, lens thickness (LT), central corneal thickness (CCT) and white-to-white

250 nterior chamber depth (ACD), lens thickness (LT), corneal power (CP), noncycloplegic subjective refra

251 Lethal thresholds (LT) of 505 V/cm and 1316 V/cm were found for brain cance

252 ected nonhuman primates and lymphoid tissue (LT) biopsies from infected humans.

253 ents (29%) died without having had access to LT.

254 efined as time from initial HCC diagnosis to LT, was less than 6 months in 32.4%, 6 to 18 months in 5

255 for HCV patients with HCC or DCC relative to LT is an important area of clinical and policy research;

256 tem (PDS) with or without heat-labile toxin (LT) from Escherichia coli or subcutaneously with aluminu

257 oteins combine to form anthrax lethal toxin (LT), whose proximal targets are mitogen-activated kinase

258 me superfamily, the lytic transglycosylases (LTs), occupies the space between the two membranes of Gr

259 Liver transplant (LT) candidates today are older, have greater medical sev

260 formance Status (KPS), and liver transplant (LT) costs in the first posttransplant year.

261 ciated with increased post-liver transplant (LT) mortality.

262 be treated for HCV before liver transplant (LT) to eliminate the virus before surgery.

263 We analyzed trends in liver transplant (LT) wait-listing (WL) to explore potential impact of eff

264 C) who are listed for liver transplantation (LT) are often treated while on the waiting list with loc

265 o cirrhosis requiring liver transplantation (LT) before the age of 40.

266 perative period after liver transplantation (LT) between donation after circulatory death (DCD) and d

267 ts with HCC requiring liver transplantation (LT) but do not include objective measures of tumor biolo

268 diagnosed in 2-6% of liver transplantation (LT) candidates.

269 k of malignancy after liver transplantation (LT) compared to other LT recipients.

270 ce and survival after liver transplantation (LT) in patients meeting Milan criteria (MC).

271 Liver transplantation (LT) is rarely indicated in the management of iatrogenic

272 cer (HCC) waiting for liver transplantation (LT) is still ongoing.

273 Although the value of liver transplantation (LT) is well established, its place in the management of

274 ression, and death in liver transplantation (LT) recipients with preformed or de novo HLA donor-speci

275 s (HBV) recurrence in liver transplantation (LT) recipients, but HBIG is costly and inconvenient to a

276 e whole experience of liver transplantation (LT) with donors >/=70 years in a single center not apply

277 tion before and after liver transplantation (LT), and its association with center characteristics, is

278 HCC) recurrence after liver transplantation (LT), but no reliable risk score has been established to

279 nt complication after liver transplantation (LT), but the role of pre-existing renal insufficiency an

280 or use related to the liver transplantation (LT), may cause worse outcomes in CLKT.

281 -fetoprotein (AFP) at liver transplantation (LT), microvascular invasion, and the sum of the largest

282 inoma (HCC) following liver transplantation (LT).

283 lular carcinoma after liver transplantation (LT).

284 er disease system for liver transplantation (LT).

285 ver disease requiring liver transplantation (LT).

286 After lung transplantation (LT), early prediction of grade 3 pulmonary graft dysfunc

287 n ultimately requiring lung transplantation (LT).

288 ously and 7 worsened (liver transplantation [LT] (n=5), deceased (n=2)).

289 rospective cohort study of adults undergoing LT for HCC between January 2001 and December 2012.

290 aluating SLK outcomes in patients undergoing LT for hepatocellular carcinoma (HCC).

291 meet Milan criteria by imaging and underwent LT between 2012 and -2014.

292 ting Milan criteria by imaging who underwent LT at the University of Toronto transplant center using

293 he records of all the children who underwent LT between 2008 and 2014 were retrospectively analyzed.

294 ohort study involving patients who underwent LT in the 2010 to 2014 period.

295 No sex differences were found in VCD, LT, and NOP after height adjustment.

296 urvival of patients treated with CLRT versus LT, stratified by the stage of liver disease, extent of

297 -volume (ST/LV) and long travel/high-volume (LT/HV) cohorts.

298 ndependent predictors of recurrence, whereas LT type was not.

299 sity prevalence was strongly associated with LT waitlist additions 9 years later in derivation and va

300 ion of rBet v 1 with PDS in combination with LT from E. coli induced allergen-specific IgG antibodies